Lymphoma Clinical Trials in Atlanta

Showing 361-380 of 543 trials

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

NCT03106428

To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected hematological malignancies who have relapsed after, or are refractory to prior standard therapy, and for whom there is no standard salvage regimen available.

Acute Myeloid LeukemiaMultiple MyelomaDiffuse Large B-cell Lymphoma

MedImmune LLC67 participantsStarted Mar 2017

Los Angeles, California, United States • Denver, Colorado, United States • Atlanta, Georgia, United States +11 more locations

COMPLETED< 1 mile

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Peripheral T-cell Lymphoma

Acrotech Biopharma Inc.3,000 participantsStarted Feb 2010

Tuscaloosa, Alabama, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +65 more locations

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Lymphoma Trials in Other Cities

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

The Second Multicenter Hemophilia Cohort Study

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Other Conditions in Atlanta